(S)-2-Cyclohexylamino-3-mercapto-propionic acid | 403804-47-7

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 英文名称: (S)-2-Cyclohexylamino-3-mercapto-propionic acid
• 英文别名: (2S)-2-(cyclohexylamino)-3-sulfanylpropanoic acid
• CAS: 403804-47-7
• 化学式: C₉H₁₇NO₂S
• 分子量: 203.305
• InChiKey: HIXDNSSPKFYZIW-MRVPVSSYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  -0.8
• 重原子数：
  13
• 可旋转键数：
  4
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.89
• 拓扑面积：
  50.3
• 氢给体数：
  3
• 氢受体数：
  4

反应信息

• 作为产物：
  描述：

  D-cysteine 、 环己酮 在 sodium cyanoborohydride 作用下， 以 甲醇 为溶剂， 生成 (S)-2-Cyclohexylamino-3-mercapto-propionic acid
  参考文献：
  名称：

  Cysteine Derivatives as Inhibitors for Carboxypeptidase A:  Synthesis and Structure−Activity Relationships

  摘要：

  A series of cysteine (Cys) derivatives having an alkyl or arylalkyl moiety on the a-amino group of the amino acid have been synthesized as a novel type of inhibitor for carboxypeptidase A. These compounds are readily prepared starting with Cys in an optically active form. The structure-activity relationship study revealed that the inhibitors prepared from D-Cys are much more potent than the corresponding inhibitors obtained from L-CYS, and the most potent inhibitor in the series, (S)-1j with a K-i value of 55 +/- 4 nM, is obtained by introducing a phenethyl moiety on the amino group Of D-CyS. In comparison, the most active inhibitor in the series of 2-substituted 3-mercaptopropanoic acid is found to be 20, in which the phenyl ring is linked to the mercaptocarboxylic acid at the a-position with a methylene unit. A proposal that accounts for the different structural requirement for the maximum activity between the two series of inhibitors is provided.

  DOI：

  10.1021/jm010272s

文献信息

• Urea derivative, process for producing the same, and use
  申请人：Kubo Keiji

  公开号：US20070093501A1

  公开（公告）日：2007-04-26

  The present invention provides a urea derivative or a salt thereof, which is useful as a therapeutic agent for thrombosis. The derivative is represented by Formula (I): wherein Cy is an aromatic hydrocarbon group which may be substituted or an aromatic heterocyclic group which may be substituted; R 1 is a hydrogen atom or a hydrocarbon group which may be substituted; V is —C(O)—, —S(O)—, or —S(O) 2 —; W is —N(R 2 )—, —O—, or a bond (wherein R 2 is a hydrogen atom or a hydrocarbon group which may be substituted); X is alkylene which may be substituted; Y is —C(O)—, —S(O)—, or —S(O) 2 —; Z is a bond, a chain hydrocarbon group which may be substituted, or —N═; ring A is a non-aromatic nitrogen-containing heterocyclic ring which may be substituted; ring B is a nitrogen-containing heterocyclic ring which may be substituted; and [Chemical formula 2] , are each independently a single bond or a double bond; provided that R 1 may be bonded to R 2 to form a non-aromatic nitrogen-containing heterocyclic ring and that R 2 may be bonded to a substituent of X to form a non-aromatic nitrogen-containing heterocyclic ring which may be substituted.

  本发明提供一种尿素衍生物或其盐，其作为治疗血栓症的治疗剂是有用的。该衍生物由公式（I）表示：其中，Cy是芳香族羟基烃基或芳香族杂环基，可以被取代；R1是氢原子或可以被取代的碳氢基团；V是-C（O）-，-S（O）-或-S（O）2-；W是-N（R2）-，-O-或键（其中R2是氢原子或可以被取代的碳氢基团）；X是可以被取代的烷基；Y是-C（O）-，-S（O）-或-S（O）2-；Z是键，可以被取代的链烃基团或-N═；环A是非芳香族含氮杂环环，可以被取代；环B是含氮杂环环，可以被取代；而[化学式2]都是单键或双键；但是，R1可以与R2连接形成非芳香族含氮杂环环，而R2可以与X的取代基连接形成可以被取代的非芳香族含氮杂环环。
• Cyclic peptides and use thereof
  申请人：TAKEDA CHEMICAL INDUSTRIES, LTD.

  公开号：EP0528312A2

  公开（公告）日：1993-02-24

  Disclosed are (1) a cyclic hexapeptide represented by formula [I] or a salt thereof: wherein X and Y each represent a-amino acid residues, A represents a D-acidic-a-amino acid residue, B represents a neutral-a-amino acid residue, C represents an L-a-amino acid residue and D represents a D-a-amino acid residue having an aromatic ring group; and (2) a pharmaceutical composition comprising the peptide represented by formula [I] or a pharmaceutically acceptable salt thereof as an active ingredient.

  公开了 (1) 由式 [I] 表示的环六肽或其盐： 其中 X 和 Y 分别代表 a-氨基酸残基，A 代表 D-酸性-a-氨基酸残基，B 代表中性-a-氨基酸残基，C 代表 L-a-氨基酸残基，D 代表具有芳香环基的 D-a-氨基酸残基；以及 (2) 一种药物组合物，其活性成分包含式 [I] 所代表的肽或其药学上可接受的盐。
• Methods and compositions for the prophylactic and/or therapeutic treatment of organ hypofunction
  申请人：TAKEDA CHEMICAL INDUSTRIES, LTD.

  公开号：EP0626174A2

  公开（公告）日：1994-11-30

  Compounds having antagonistic activity on endothelin receptors can be effectively used for prophylaxis and/or treatment of hypofunction of organs which occurs in their surgery or transplant.

  对内皮素受体具有拮抗活性的化合物可有效用于预防和/或治疗器官移植手术中出现的器官功能减退。
• Sustained-release preparation of anti-endothelin substance
  申请人：Takeda Chemical Industries, Ltd.

  公开号：EP0647449A1

  公开（公告）日：1995-04-12

  A sustained-release preparation containing an anti-endothelin substance and a biodegradable polymer. The sustained-release preparation of the present invention sustainedly releases an anti-endothelin substance, serving well in the treatment of endothelin-associated diseases.

  一种含有抗内皮素物质和生物可降解聚合物的缓释制剂。 本发明的缓释制剂能持续释放抗内皮素物质，可用于治疗内皮素相关疾病。
• Composition for prophylaxis or treatment of pulmonary circulatory diseases
  申请人：Takeda Chemical Industries, Ltd.

  公开号：EP0714909A1

  公开（公告）日：1996-06-05

  Cyclic hexapeptides having antagonistic activity on endothelin receptors of the formula [I]: wherein X and Y each is an α-amino acid residue having D-, L-form or DL-form, A is a D-acidic-α-amino acid residue, B is a neutral-α-amino acid residue having D- or L-form, C is an L-α-amino acid residue and E is a D-α-amino acid residue having an aromatic ring group can be effectively used for prophylaxis and/or treatment of pulmonary circulatory diseases.

  对内皮素受体具有拮抗活性的式 [I] 环六肽： 其中，X 和 Y 分别为具有 D-、L-或 DL-形式的 α-氨基酸残基，A 为 D-酸性-α-氨基酸残基，B 为具有 D-或 L-形式的中性-α-氨基酸残基，C 为 L-α-氨基酸残基，E 为具有芳香环基的 D-α-氨基酸残基，可有效用于预防和/或治疗肺循环疾病。